Improving Hepatocellular Carcinoma Screening: Applying Lessons From Colorectal Cancer Screening

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 5, 2013, Pages 472-477

  Singal, Amit G ^a,b,c   Tiro, Jasmin A ^b,c   Gupta, Samir ^a,b,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Colon Cancer; Effectiveness; Health Services Research; Liver Cancer; Process of Care; Screening

Indexed keywords

ARTICLE; CANCER SCREENING; COLONOSCOPY; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; FAMILY HISTORY; FOLLOW UP; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; LIVER CELL CARCINOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCULT BLOOD; PATIENT COMPLIANCE; PATIENT IDENTIFICATION; PATIENT REFERRAL; PRACTICE GUIDELINE; SIGMOIDOSCOPY; SOCIAL STATUS;

CARCINOMA, HEPATOCELLULAR; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; HUMANS; LIVER NEOPLASMS;

EID: 84875224556     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.11.010     Document Type: Article

References (63)

1. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
2. Singal A.G., Marrero J.A. Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroenterol 2010, 26:189-195.
3. Llovet J.M., Bustamante J., Castells A., et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999, 29:62-67.
4. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334:693-699.
5. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236. Practice Guidelines Committee, American Association for the Study of Liver Diseases.
6. Taplin S.H., Rodgers A.B. Toward improving the quality of cancer care: addressing the interfaces of primary and oncology-related subspecialty care. J Natl Cancer Inst Monogr 2010, 2010:3-10.
7. Zapka J.G., Taplin S.H., Solberg L.I., et al. A framework for improving the quality of cancer care: the case of breast and cervical cancer screening. Cancer Epidemiol Biomarkers Prev 2003, 12:4-13.
8. Singal A., Volk M.L., Waljee A., et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009, 30:37-47.
9. Singal A.G., Conjeevaram H.S., Volk M.L., et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev 2012, 21:793-799.
10. Leyden W.A., Manos M.M., Geiger A.M., et al. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. J Natl Cancer Inst 2005, 97:675-683.
11. Taplin S.H., Ichikawa L., Yood M.U., et al. Reason for late-stage breast cancer: absence of screening or detection, or breakdown in follow-up?. J Natl Cancer Inst 2004, 96:1518-1527.
12. Edwards B.K., Ward E., Kohler B.A., et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010, 116:544-573.
13. Joseph D.A., King J.B., Miller J.W., et al. Prevalence of colorectal cancer screening among adults-behavioral risk factor surveillance system, United States. MMWR Morb Mortal Wkly Rep 2010, 61(Suppl):51-56.
14. Klabunde C.N., Brown M., Ballard-Barbash R., et al. Cancer screening-United States, 2010. MMWR Morb Mortal Wkly Rep 2012, 61:41-45.
15. Steinwachs D., Allen J.D., Barlow W.E., et al. National Institutes of Health state-of-the-science conference statement: enhancing use and quality of colorectal cancer screening. Ann Intern Med 2010, 152:663-667.
16. Ransohoff D.F. Colon cancer screening in 2005: status and challenges. Gastroenterology 2005, 128:1685-1695.
17. Altekruse S.F., McGlynn K.A., Reichman M.E. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009, 27:1485-1491.
18. Davila J.A., Henderson L., Kramer J.R., et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med 2011, 154:85-93.
19. Davila J.A., Morgan R.O., Richardson P.A., et al. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology 2010, 52:132-141.
20. Singal A.G., Yopp A., Skinner C., et al. Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review. J Gen Intern Med 2012, 27:861-867.
21. Schroy P.C., Barrison A.F., Ling B.S., et al. Family history and colorectal cancer screening: a survey of physician knowledge and practice patterns. Am J Gastroenterol 2002, 97:1031-1036.
22. Singal A.G., Yopp A.C., Gupta S., et al. Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev Res (Phila) 2012, 5:1124-1130.
23. Stravitz R.T., Heuman D.M., Chand N., et al. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med 2008, 121:119-126.
24. Rockey D.C., Caldwell S.H., Goodman Z.D., et al. Liver biopsy. Hepatology 2009, 49:1017-1044.
25. Williams C.D., Stengel J., Asike M.I., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011, 140:124-131.
26. Tomaszewski K.J., Deniz B., Tomanovich P., et al. Comparison of current US risk strategy to screen for hepatitis C virus with a hypothetical targeted birth cohort strategy. Am J Public Health 2012, 102:e101-e106.
27. Szymczak A., Simon K., Inglot M., et al. Safety and effectiveness of blind percutaneous liver biopsy: analysis of 1412 procedures. Hepat Mon 2012, 12:32-37.
28. Lin Z.H., Xin Y.N., Dong Q.J., et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011, 53:726-736.
29. Kramer J.R., Davila J.A., Miller E.D., et al. The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases. Aliment Pharmacol Ther 2008, 27:274-282.
30. Nehra M.S., Ma Y., Clark C., et al. Use of administrative claims data for identifying patients with cirrhosis. J Clin Gastroenterol 2012 Oct 18, Epub ahead of print.
31. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008, 149:627-637. US Preventive Services Task Force.
32. Smith R.A., Cokkinides V., Brooks D., et al. Cancer screening in the United States, 2011: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2011, 61:8-30.
33. Dulai G.S., Farmer M.M., Ganz P.A., et al. Primary care provider perceptions of barriers to and facilitators of colorectal cancer screening in a managed care setting. Cancer 2004, 100:1843-1852.
34. Klabunde C.N., Vernon S.W., Nadel M.R., et al. Barriers to colorectal cancer screening: a comparison of reports from primary care physicians and average-risk adults. Med Care 2005, 43:939-944.
35. Fenton J.J., Reid R.J., Baldwin L.M., et al. Influence of primary care use on population delivery of colorectal cancer screening. Cancer Epidemiol Biomarkers Prev 2009, 18:640-645.
36. Orlandi M.A. Promoting health and preventing disease in health care settings: an analysis of barriers. Prev Med 1987, 16:119-130.
37. Pommerenke F.A., Dietrich A. Improving and maintaining preventive services, part 2: practical principles for primary care. J Fam Pract 1992, 34:92-97.
38. Levin T.R., Jamieson L., Burley D.A., et al. Organized colorectal cancer screening in integrated health care systems. Epidemiol Rev 2011, 33:101-110.
39. McPhee S.J., Bird J.A., Jenkins C.N., et al. Promoting cancer screening. A randomized, controlled trial of three interventions. Arch Intern Med 1989, 149:1866-1872.
40. Updated recommendations for client- and provider-oriented interventions to increase breast, cervical, and colorectal cancer screening. Am J Prev Med 2012, 43:92-96. Community Preventive Services Task Force.
41. Sabatino S.A., Lawrence B., Elder R., et al. Effectiveness of interventions to increase screening for breast, cervical, and colorectal cancers: nine updated systematic reviews for the guide to community preventive services. Am J Prev Med 2012, 43:97-118.
42. Tape T.G., Campbell J.R. Computerized medical records and preventive health care: success depends on many factors. Am J Med 1993, 94:619-625.
43. Singal A.G., Nehra M., Adams-Huet B., et al. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail?. Am J Gastroenterol 2013 Jan 22, Epub ahead of print.
44. Freedman J.D., Mitchell C.K. A simple strategy to improve patient adherence to outpatient fecal occult blood testing. J Gen Intern Med 1994, 9:462-464.
45. Turner B.J., Weiner M., Yang C., et al. Predicting adherence to colonoscopy or flexible sigmoidoscopy on the basis of physician appointment-keeping behavior. Ann Intern Med 2004, 140:528-532.
46. Kaminski M.F., Regula J., Kraszewska E., et al. Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med 2010, 362:1795-1803.
47. Christie J., Itzkowitz S., Lihau-Nkanza I., et al. A randomized controlled trial using patient navigation to increase colonoscopy screening among low-income minorities. J Natl Med Assoc 2008, 100:278-284.
48. Lasser K.E., Murillo J., Lisboa S., et al. Colorectal cancer screening among ethnically diverse, low-income patients: a randomized controlled trial. Arch Intern Med 2011, 171:906-912.
49. Percac-Lima S., Grant R.W., Green A.R., et al. A culturally tailored navigator program for colorectal cancer screening in a community health center: a randomized, controlled trial. J Gen Intern Med 2009, 24:211-217.
50. Singal A.G., Volk M.L., Rakoski M.O., et al. Patient involvement in healthcare is associated with higher rates of surveillance for hepatocellular carcinoma. J Clin Gastroenterol 2011, 45:727-732.
51. Shebl F.M., Capo-Ramos D.E., Graubard B.I., et al. Socioeconomic status and hepatocellular carcinoma in the United States. Cancer Epidemiol Biomarkers Prev 2012, 21:1330-1335.
52. Seeff L.C., Manninen D.L., Dong F.B., et al. Is there endoscopic capacity to provide colorectal cancer screening to the unscreened population in the United States?. Gastroenterology 2004, 127:1661-1669.
53. Goldman L.E., Henderson S., Dohan D.P., et al. Public reporting and pay-for-performance: safety-net hospital executives' concerns and policy suggestions. Inquiry 2007, 44:137-145.
54. Humphrey L.L., Shannon J., Partin M.R., et al. Improving the follow-up of positive hemoccult screening tests: an electronic intervention. J Gen Intern Med 2011, 26:691-697.
55. Jimbo M., Myers R.E., Meyer B., et al. Reasons patients with a positive fecal occult blood test result do not undergo complete diagnostic evaluation. Ann Fam Med 2009, 7:11-16.
56. Kistler C.E., Kirby K.A., Lee D., et al. Long-term outcomes following positive fecal occult blood test results in older adults: benefits and burdens. Arch Intern Med 2011, 171:1344-1351.
57. Miglioretti D.L., Rutter C.M., Bradford S.C., et al. Improvement in the diagnostic evaluation of a positive fecal occult blood test in an integrated health care organization. Med Care 2008, 46:S91-S96.
58. Powell A.A., Gravely A.A., Ordin D.L., et al. Timely follow-up of positive fecal occult blood tests strategies associated with improvement. Am J Prev Med 2009, 37:87-93.
59. Powell A.A., Nugent S., Ordin D.L., et al. Evaluation of a VHA collaborative to improve follow-up after a positive colorectal cancer screening test. Med Care 2011, 49:897-903.
60. Rao S.K., Schilling T.F., Sequist T.D. Challenges in the management of positive fecal occult blood tests. J Gen Intern Med 2009, 24:356-360.
61. Singh H., Daci K., Petersen L.A., et al. Missed opportunities to initiate endoscopic evaluation for colorectal cancer diagnosis. Am J Gastroenterol 2009, 104:2543-2554.
62. Singh H., Kadiyala H., Bhagwath G., et al. Using a multifaceted approach to improve the follow-up of positive fecal occult blood test results. Am J Gastroenterol 2009, 104:942-952.
63. Kubota K., Ina H., Okada Y., et al. Growth rate of primary single hepatocellular carcinoma: determining optimal screening interval with contrast enhanced computed tomography. Dig Dis Sci 2003, 48:581-586.